<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191188</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2014-1144</org_study_id>
    <nct_id>NCT03191188</nct_id>
  </id_info>
  <brief_title>A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients</brief_title>
  <official_title>A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine
      complication of chronic kidney disease that has been associated with impaired quality of life
      and cardiovascular complications. While levothyroxine is one of the most frequently
      prescribed medications in chronic kidney disease patients, little is known about its efficacy
      and safety in this population. This study will investigate 1) whether levothyroxine
      adequately lowers thyrotropin (TSH) levels to therapeutic target ranges, and 2) if thyroid
      hormone replacement improves quality of life and cardiovascular markers, without leading to
      wasting in dialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of target TSH levels: serum TSH levels ranging from 0.5-3.0mIU/L</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of patients achieving target TSH levels of 0.5-3.0mIU/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life Short Form 36 questionnaire</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Short Form 36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Growth Differentiation Factor 15 (GDF15) level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in GDF15 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum soluble p-selectin level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in soluble p-selectin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum soluble CD40 ligand level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in serum soluble CD40 ligand level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biceps skinfold</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in biceps skinfold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triceps skinfold</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in triceps skinfold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid-arm circumference</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in mid-arm circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid-arm muscle circumference</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in mid-arm muscle circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Near infrared body fat percentage</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in near infrared body fat percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Global Assessment questionnaire</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Subjective Global Assessment questionnaire score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Thyroid Disease</condition>
  <condition>Kidney Diseases, Chronic</condition>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Sodium</intervention_name>
    <description>Thyroid hormone supplement</description>
    <arm_group_label>Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prevalent hemodialysis patients, elevated thyrotropin level, normal free thyroxine
             level.

        Exclusion Criteria:

          -  Hyperthyroidism, active treatment with thyroid hormone replacement, prior thyroid
             malignancy, active pregnancy, active coronary ischemia or atrial fibrillation,
             osteoporosis, inability to provide consent without a proxy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie M. Rhee, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Connie M. Rhee, MD, MSc</last_name>
    <phone>714-456-5142</phone>
    <email>crhee1@uci.edu</email>
  </overall_contact>
  <reference>
    <citation>Rhee CM, You AS, Nguyen DV, Brunelli SM, Budoff MJ, Streja E, Nakata T, Kovesdy CP, Brent GA, Kalantar-Zadeh K. Thyroid Status and Mortality in a Prospective Hemodialysis Cohort. J Clin Endocrinol Metab. 2017 May 1;102(5):1568-1577. doi: 10.1210/jc.2016-3616.</citation>
    <PMID>28324018</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Kim S, Gillen DL, Oztan T, Wang J, Mehrotra R, Kuttykrishnan S, Nguyen DV, Brunelli SM, Kovesdy CP, Brent GA, Kalantar-Zadeh K. Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015 Apr;100(4):1386-95. doi: 10.1210/jc.2014-4311. Epub 2015 Jan 29.</citation>
    <PMID>25632971</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Ravel VA, Streja E, Mehrotra R, Kim S, Wang J, Nguyen DV, Kovesdy CP, Brent GA, Kalantar-Zadeh K. Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort. J Clin Endocrinol Metab. 2016 Nov;101(11):4054-4061. Epub 2016 Aug 15.</citation>
    <PMID>27525529</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Kalantar-Zadeh K, Streja E, Carrero JJ, Ma JZ, Lu JL, Kovesdy CP. The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease. Nephrol Dial Transplant. 2015 Feb;30(2):282-7. doi: 10.1093/ndt/gfu303. Epub 2014 Sep 21.</citation>
    <PMID>25246335</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Connie Rhee</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

